...
首页> 外文期刊>International Journal of Hematology and Oncology >Acute in Vitro effects of ABS (Ankaferd Hemostat) on the Lymphoid Neoplastic Cells (B-CLL and RAJI Tumor Cell Lines)
【24h】

Acute in Vitro effects of ABS (Ankaferd Hemostat) on the Lymphoid Neoplastic Cells (B-CLL and RAJI Tumor Cell Lines)

机译:ABS(Ankaferd Hemostat)对淋巴肿瘤细胞(B-CLL和RAJI肿瘤细胞系)的急性体外作用

获取原文
           

摘要

ABS (Ankaferd Hemostat) has emerged as a novel haemostatic agent of plant origin. Its ability to interact with entire proteins including cell surface receptors and/or blood proteins plus tissue proteins revealed novel functions of ABS to biologic systems especially tumor associated transcription factors. Thus, in our study, we aimed to investigate the effects of ABS on lymphoid neoplastic cells in vitro. We showed that Ankaferd treated B-CLL cells (at doses 0.5, 1 and 2 μg/mL) ceased to inflate and more than 50% of tumor cells were died compared to 0.1 and 0.25 μg/mL doses. Additionally, transformation of B-CLL cells to the blastic aggressive lymphoid forms was prevented by addition of Ankaferd to culture medium. The results have given the clues of anti-neoplastic effects at higher doses (>0.5 μg/mL) and induction of cellular differentiation at lower doses (
机译:ABS(Ankaferd Hemostat)已作为一种新型的植物止血剂出现。它与包括细胞表面受体和/或血液蛋白以及组织蛋白在内的整个蛋白相互作用的能力揭示了ABS对生物系统特别是肿瘤相关转录因子的新功能。因此,在我们的研究中,我们旨在研究ABS对体外淋巴瘤细胞的影响。我们显示,经Ankaferd处理的B-CLL细胞(剂量分别为0.5、1和2μg/ mL)停止膨胀,与0.1和0.25μg/ mL剂量相比,超过50%的肿瘤细胞死亡。另外,通过向培养基中添加Ankaferd,防止了B-CLL细胞转化为侵袭性淋巴样细胞形式。结果提供了高剂量(> 0.5μg/ mL)时抗肿瘤作用和低剂量(> 0.5μg/ mL)诱导细胞分化的线索

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号